Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 1455 results for ages

  1. Age-related macular degeneration (NG82)

    This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

  2. Faricimab for treating wet age-related macular degeneration (TA800)

    Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.

  3. Brolucizumab for treating wet age-related macular degeneration (TA672)

    Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

  4. Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)

    Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.

  5. Miniature lens system implantation for advanced age-related macular degeneration

    Topic prioritisation

  6. Radiotherapy for age-related macular degeneration (HTG24)

    Evidence-based recommendations on radiotherapy for age-related macular degeneration. This involves using radiation to destroy the new blood vessels, with the aim of slowing down sight loss.

  7. High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]

    Topic prioritisation

  8. Developmental follow-up of children and young people born preterm (NG72)

    This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.

  9. Transpupillary thermotherapy for age-related macular degeneration (HTG31)

    Evidence-based recommendations on transpupillary thermotherapy for age-related macular degeneration. This involves using a laser to heat and seal up the blood vessels that are causing the problems.

  10. Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

    Awaiting development Reference number: GID-TA10879 Expected publication date:  11 November 2026

  11. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC

  12. Epiretinal brachytherapy for wet age-related macular degeneration (HTG279)

    Evidence-based recommendations on epiretinal brachytherapy for wet age related macular degeneration. This involves using radiation therapy used to destroy the new blood vessels.

  13. Miniature lens system implantation for advanced age-related macular degeneration (HTG418)

    Evidence-based recommendations on miniature lens system implantation for advanced age-related macular degeneration. This involves implanting an artificial lens system into 1 eye only.

  14. Limited macular translocation for wet age-related macular degeneration (HTG215)

    Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.

  15. Digital technologies to support monitoring of vision change at home for people with age-related macular degeneration: early use assessment

    In development Reference number: GID-HTE10073 Expected publication date:  15 September 2026